Development and validation of an HPLC method to quantify 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids

Biomedical Chromatography

Volumn 23, Issue 8, 2009, Pages 843-851

  Frischmann, Matthias ^a   Spitzer, Johanna ^a   Fünfrocken, Michael ^b   Mittelmaier, Stefan ^a   Deckert, Melanie ^a   Fichert, Thomas ^b   Pischetsrieder, Monika ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b FRESENIUS MEDICAL CARE   (Germany)

Author keywords

3,4 Dideoxyglucosone 3 ene (3,4 DGE); Glucose degradation products (GDP); HPLC; Peritoneal dialysis fluid (PD fluid)

Indexed keywords

ACETALDEHYDE; DEGRADATION; DIALYSIS; GLUCOSE;

3,4-DIDEOXYGLUCOSONE-3-ENE; DEGRADATION PRODUCTS; GLUCOSE DEGRADATION; GLUCOSE DEGRADATION PRODUCT; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HPLC; HPLC METHOD; PERITONEAL DIALYSIS FLUID; PERITONEAL DIALYSIS FLUIDS; UV DETECTION;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

1,2 PHENYLENEDIAMINE; 3 DEOXYGLUCOSONE; 3,4 DIDEOXYGLUCOSONE 3 ENE; 5 HYDROXYMETHYLFURFURAL; ACETALDEHYDE; FORMALDEHYDE; FURFURAL; GLYOXAL; METHYLGLYOXAL; PERITONEAL DIALYSIS FLUID; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DERIVATIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERITONEAL DIALYSIS; ULTRAVIOLET RADIATION; ULTRAVIOLET SPECTROPHOTOMETRY;

EID: 70349478899     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1194     Document Type: Article

References (34)

1. Anet EF. Degradation of carbohydrates. Australian Journal of Chemistry 1962; 15: 503-509.
2. Anet EF. 3-Deoxyglycosuloses (3-deoxyglycosones) and the degradation of carbohydrates. Advances in Carbohydrate Chemistry 1964; 19: 181-218.
3. Bravo A, Herrera JC, Scherer E, Ju-Nam Y, Rubsam H, Madrid J, Zufall C and Rangel-Aldao R. Formation of alpha-dicarbonyl compounds in beer during storage of Pilsner. Journal of Agricultural and Food Chemistry 2008; 56: 4134-4144.
4. Erixon M, Linden T, Kjellstrand P, Carlsson O, Ernebrant M, Forsback G, Wieslander A and Jonsson JA. PD fluids contain high concentrations of cytotoxic GDPs directly after sterilization. Peritoneal Dialysis International 2004; 24: 392-398.
5. Erixon M, Wieslander A, Linden T, Carlsson O, Forsback G, Svensson E, Jonsson JA and Kjellstrand P. How to avoid glucose degradation products in peritoneal dialysis fluids. Peritoneal Dialysis International 2006; 26: 490-497.
6. Glomb MA and Tschirnich R. Detection of alpha-dicarbonyl compounds in Maillard reaction systems and in vivo. Journal of Agricultural and Food Chemistry 2001; 49: 5543-5550.
7. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, Ikeda K and Horiuchi S. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrology, Dialysis, Transplantation 1999; 14: 1541-1549.
8. Kato F, Mizukoshi S, Aoyama Y, Matsuoka H, Tanaka H, Nakamura K and Tsukamoto M. Immunosuppressive effects of 3,4-dideoxyglucosone-3-ene, an intermediate in the Maillard reaction. Journal of Agricultural and Food Chemistry 1994; 42: 2068-2073.
9. Lai KN, Leung JC, Chan LY, Li FF, Tang SC, Lam MF, Tse KC, Yip TP, Chan TM, Wieslander A and Vlassara H. Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clinical and Experimental Immunology 2004; 138: 466-475.
10. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim YL, Kim DJ, Kim YS, Ahn C, Kim MJ and Shin SK. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Peritoneal Dialysis International 2005; 25: 248-255.
11. Leung JC, Chan LY, Li FF, Tang SC, Chan KW, Chan TM, Lam MF, Wieslander A and Lai KN. Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF. Nephrology, Dialysis, Transplantation 2005; 20: 1336-1349.
12. Linden T, Forsback G, Deppisch R, Henle T and Wieslander A. 3- Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Peritoneal Dialysis International 1998; 18: 290-293.
13. Linden T, Musi B, Jarkelid L, Forsback G, Kjellstrand P, Deppisch R and Wieslander A. Glucose degradation products in peritoneal dialysis fluids may have both local and systemic effects: a study of residual fluid and mesothelial cells. Peritoneal Dialysis International 2001; 21: 607-610.
14. Linden T, Cohen A, Deppisch R, Kjellstrand P and Wieslander A. 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney International 2002; 62: 697-703.
15. Mahiout A, Ehlerding G and Brunkhorst R. Advanced glycation endproducts in the peritoneal fluid and in the peritoneal membrane of continuous ambulant peritoneal dialysis patients. Nephrology, Dialysis, Transplantation 1996; 11(suppl. 5): 2-6.
16. Millar DJ, Holmes C, Faict D and Dawnay A. Comparison of in vitro AGE formation between standard PD fluid and a novel bicarbonate/lactate formulation. Advances in Peritoneal Dialysis 1998; 14: 191-194.
17. Miyata T, Kurokawa K and Van Ypersele De Strihou C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. Journal of the American Society of Nephrology 2000; 11: 1744-1752.
18. Morgan LW, Wieslander A, Davies M, Horiuchi T, Ohta Y, Beavis MJ, Craig KJ, Williams JD and Topley N. Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration. Kidney International 2003; 64: 1854-1866.
19. Mortier S, De Vriese AS, Van de Voorde J, Schaub TP, Passlick-Deetjen J and Lameire NH. Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products. Journal of the American Society of Nephrology 2002; 13: 480-489.
20. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, Hayakawa H, Osaka N, Yamamoto H, Ogawa A, Kubo H, Shigematsu T, Sakai O and Horiuchi S. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney International 1997; 51: 182-186.
21. Nilsson-Thorell CB, Muscalu N, Andren AH, Kjellstrand PT and Wieslander AP. Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Peritoneal Dialysis International 1993; 13: 208-213.
22. Rodrigues JA, Barros AA and Rodrigues PG. Differential pulse polarographic determination of alpha-dicarbonyl compounds in foodstuffs after derivatization with o-phenylenediamine. Journal of Agricultural and Food Chemistry 1999; 47: 3219-3222.
23. Schalkwijk CG, Posthuma N, ten Brink HJ, ter Wee PM and Teerlink T. Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids. Peritoneal Dialysis International 1999; 19: 325-333.
24. Tauer A, Knerr T, Niwa T, Schaub TP, Lage C, Passlick-Deetjen J and Pischetsrieder M. In vitro formation of N(epsilon)-(carboxymethyl) lysine and imidazolone under conditions similar to continuous ambulatory peritoneal dialysis. Biochemical and Biophysical Research Communications 2001; 280: 1408-1414.
25. Tauer A, Zhang X, Schaub TP, Zimmeck T, Niwa T, Passlick-Deetjen J and Pischetsrieder M. Formation of advanced glycation end products during CAPD. American Journal of Kidney Diseases 2003; 41: S57-60.
26. Tauer A, Bender TO, Fleischmann EH, Niwa T, Jorres A and Pischetsrieder M. Fate of the glucose degradation products 3-deoxyglucosone and glyoxal during peritoneal dialysis. Molecular Nutrition and Food Research 2005; 49: 710-715.
27. Tomo T, Okabe E, Yamamoto T, Namoto S, Iwashita T, Matsuyama K, Kadota J and Nasu M. Synergistic cytotoxicity of acidity and 3,4- dideoxyglucosone-3-ene under the existence of lactate in peritoneal dialysis fluid. Therapeutic Apheresis and Dialysis 2005; 9: 182-187.
28. Ueda Y, Miyata T, Goffin E, Yoshino A, Inagi R, Ishibashi Y, Izuhara Y, Saito A, Kurokawa K and Van Ypersele De Strihou C. Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids. Kidney International 2000; 58: 2518-2524.
29. Weenen H and Tjan B. Analysis, Structure, and Reactivity of 3-Deoxyglucosone, Flavor Precursors. American Chemical Society: New York, 1992; 217-231.
30. Wieslander AP, Deppisch R, Svensson E, Forsback G, Speidel R and Rippe B. In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis. Peritoneal Dialysis International 1995; 15: 158-164.
31. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C and Passlick-Deetjen J. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney International 2004; 66: 408-418.
32. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J and Jorres A. Effect of glucose degradation products on human peritoneal mesothelial cell function. Journal of the American Society of Nephrology 2000; 11: 729-739.
33. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T and Ritz E. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney International 2003; 63: 298-305.
34. Zimmeck T, Tauer A, Fuenfrocken M and Pischetsrieder M. How to reduce 3-deoxyglucosone and acetaldehyde in peritoneal dialysis fluids. Peritoneal Dialysis International 2002; 22: 350-356.